The new nomenclature considers the autoantigen involved (MPO/PR3) adding the relevant clinical manifestations, preferably using the terms GPA/MPA/EGPA, where present (e.g., PR3-AAV with clinical manifestations of GPA) (159). This evidence concerns the gene MPO and anti-neutrophil cytoplasmic antibody-associated vasculitis.